LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Strona główna・Stock List・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Closed

SectorHealthcare

5 0.2

Buy Sell

Overview

Share price change

24h

Current

Min

4.91

Max

5.07

Key metrics
By Trading Economics
Income	36M -3.7M
Sales	16M 66M
EPS	0.01
Profit margin	-5.67
Employees	416
EBITDA	57M 15M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+17.15% upside

Dividends
By Dow Jones
Next Earnings	10 sie 2026

Market Stats
By TradingEconomics
Market Cap	354M 1.8B
Previous open	4.8
Previous close	5

News Sentiment

By Acuity

50%

155 / 344 Ranking in Healthcare

Maravai LifeSciences Holdings Inc (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 cze 2026, 19:20 UTC

Major Market Movers

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 cze 2026, 21:27 UTC

Earnings

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 cze 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 cze 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 cze 2026, 20:19 UTC

Acquisitions, Mergers, Takeovers

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 cze 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 cze 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 cze 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 cze 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 cze 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 cze 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 cze 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 cze 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 cze 2026, 18:33 UTC

Acquisitions, Mergers, Takeovers

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 cze 2026, 17:50 UTC

Earnings

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 cze 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 cze 2026, 16:48 UTC

Acquisitions, Mergers, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 cze 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 cze 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 cze 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 cze 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 cze 2026, 15:44 UTC

Acquisitions, Mergers, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 cze 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 cze 2026, 15:25 UTC

Earnings

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 cze 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 cze 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5 cze 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 cze 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 cze 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

17.15% upside

12 Months Forecast

Average 5.67 USD 17.15%

High 6 USD

Low 5 USD

Based on 5 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Maravai LifeSciences Holdings Inc (Class A) - Dist in the past 3 months.

Sentiment

By Acuity

155 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.